Associate Clinical Professor of Medicine, USC-Keck School of Medicine
Oncology
Dr. Barbara J. Gitlitz, MD
|
|
Give Review
Barbara Gitlitz is an expert in the field of Oncology. He graduated from Stony Brook University School of Medicine. He received awards:"Top Doctors:LA Area", "Top Doctors:Southern California" and "Super Doctor". Barbara Gitlitz is a published physician. He published 50 publications, including: 'Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.' He accepts all Medicare patients.
Publications
- Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWO...
- I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive Disease while on alectinib and is sen...
- Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of Southwest Oncolog...
- Phase I clinical trial of temsirolimus and vinorelbine in advanced solid Tumors.
- A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lu...
- Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid Tumors.
- Adoptive cellular therapy.
- Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in Cancer pa...
- Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell c...
- Immunologic approaches to the treatment of Cancer.
- Immunotherapy and gene therapy.
- Reevaluation of the 1997 TNM classification for renal cell Carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome.
- Vaccine and gene therapy of renal cell Carcinoma.
- Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an Analysis of 124 consecutively treated patients.
- Improved prognostication of renal cell carcinoma using an integrated staging System.
- Dendritic cell-based immunotherapy of renal cell Carcinoma.
- Mathematical model to predict individual survival for patients with renal cell Carcinoma.
- Collecting duct renal cell Carcinoma: clinical study of a rare tumor.
- Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell Carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monoc...
- A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid Cancers: a ...
- Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003).
- Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung Cancer treated with erlotinib.
- Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung Cancer: a California Cancer consortium trial.
- Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung Cancer.
- Sorafenib in platinum-treated patients with extensive stage small cell lung Cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
- Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung Cancer.
- Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid Tumors.
- Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung Cancer.
- Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced Malignant pleural mesothelioma.
- Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid Tumors that express the IL-4 receptor.
- Metastatic renal cell Carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment.
- Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate Cancer.
- Cell, gene and vaccine based strategies in kidney Cancer.
- A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial Carcinoma.
- A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell Carcinoma.
- Cytokine-based therapy for metastatic renal cell Cancer.
- Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to Cancer patients.
- Renal cell Carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.
- Renal cell Carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.
- Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with Cancer.
- Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell Carcinoma.
- Renal cell Carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy.
- Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate Cancer clones expressing distinct cellular and molecular properties not pres...
- Cytoreductive surgery in the management of metastatic renal cell Carcinoma: the UCLA experience.
- Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney Cancer va...
- Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell Carcinoma.
- Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an Analysis of 203 consecutively treated patients.
- Treatment of metastatic renal cell Carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.
- Caring for children in foster care.
Schools
Stony Brook Univ Health Sciences Center School Of Medicine
UCLA
Cedars Sinai Med Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select PPO
- Access Plus Savenet
- Basic Exclusive PPO for Small Business
- Basic PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- Covered California - Bronze PPO
- Health Net PPO
- Individual and Family PPO
- Medicare Advantage PFFS
- Humana
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Heritage Signature
- Principal Life
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Top Doctors:LA Area
- Top Doctors:Southern California
- Super Doctor
Education
-
UCLA Medical Center -
Cedars-Sinai Medical Center -
Stony Brook University School of Medicine
Hospital
-
Keck Hospital of USC
Drug Facts
| NPI NUMBER | 1467488015 | |
| NPPES Provider LastName | GITLITZ | |
| NPPES Provider FirstName | BARBARA | |
| NPPES Provider ZIPCode | 900890112 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 515.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 26.0 | |
| Percent Opioid Claims | 5.05 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1467488015 |
| Last Name Of The Provider | GITLITZ |
| First Name Of The Provider | BARBARA |
| View All |
Similar Doctors
|
|
Dr. Mary E. Sehl, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Shahrooz Eshaghian, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Dennis R. Holmes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David S. Finley, MD |
|
|
Dr. Darcy V. Spicer, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Cary H. Gota, MD |
|
|
Dr. Aron B. Bick, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samuel D. Bernal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amir Goldkorn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James H. Breeden, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jacek K. Pinski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dennis J. Slamon, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|